Composition of anti-wrinkle cream, preparation process, and uses

Abstract

This disclosure provides an anti-wrinkle composition, a method for its preparation, and applications, all within the technical field of cosmetics. The anti-wrinkle composition according to this disclosure comprises the following components by weight: 0.1 to 1.5 parts of Aphanothece sacrum polysaccharides, 0.1 to 70 parts of Gloiopeltis furcata extract, 10 to 230 parts of butylene glycol, and 50 to 600 parts of water. The anti-wrinkle composition according to this disclosure enhances the moisturizing, refreshing, skin elasticity-improving, and anti-wrinkle effects of the anti-wrinkle composition through the synergistic actions of the Aphanothece sacrum polysaccharides and the Gloiopeltis furcata extract. Figure for the abstract: Fig 5

Description

Title of the invention: Anti-wrinkle composition and method of preparation thereof and uses. Technical field

[0001] This disclosure relates to the technical field of cosmetics, in particular an anti-wrinkle composition and a process for its preparation and uses. TECHNICAL CONTEXT

[0002] With age, metabolism slows down, the amount of water and subcutaneous fat in the body decreases, and the skin's elastic fibers gradually thicken, leading to the appearance of wrinkles and a loss of radiance. Skin aging is a clear manifestation of the overall aging of the body, and facial skin aging is particularly noticeable. The number of fibroblasts in the human body gradually decreases, and the collagen and elastin secreted by fibroblasts also diminish and gradually degrade due to oxidation, so the epidermis loses its support, resulting in uneven sagging, thinning of the dermis, loss of skin elasticity, and the gradual appearance of wrinkles.In addition to natural physiological factors, human skin aging is also linked to factors such as long-term sleep quality, ultraviolet exposure, the work environment, lifestyle habits, nutritional status, and skincare.

[0003] Although skin aging is an irreversible physiological phenomenon, it is possible to delay the aging process through aesthetic medicine or the use of cosmetic products.The wrinkle removal methods currently available on the market are as follows: (1) injection of a small dose of botulinum toxin type A, but this method can lead to serious complications and pose a serious threat to skin health; (2) the use of a combination of peptides and peptide compositions to achieve a firming and anti-wrinkle effect, but such active ingredients cannot be well absorbed by the skin, remaining only on the skin's surface, resulting in a relatively weak anti-wrinkle effect; (3) the use of polydimethylsiloxane to fill pores and crevices in the skin to achieve an immediate anti-wrinkle effect, but this method only treats the symptoms, without addressing the underlying causes.Long-term use of this method causes clogged pores, skin irritation, and can lead to acne or allergies; (4) the use of retinol-based anti-wrinkle products. Although the effect of this method... Although relatively high concentrations of retinol irritate the skin, retinol has poor stability and therefore limited bioavailability. DISCLOSURE OF THE INVENTION

[0004] The purpose of this disclosure is to overcome the drawbacks of the prior art and to provide an anti-wrinkle composition, as well as a method for its preparation and uses thereof.

[0005] To achieve the above object, the present invention proposes the following technical solution: an anti-wrinkle composition comprises the following ingredients in parts by weight: 0.1 to 1.5 parts of Aphanothece sacrum polysaccharides, 0.1 to 70 parts of Gloiopeltis furcata extract, 10 to 230 parts of butylene glycol and 50 to 600 parts of water.

[0006] According to one embodiment, the percentage by weight of Aphanothece sacrum polysaccharides in the anti-wrinkle composition varies from 0.05 to 0.5% by weight.

[0007] According to one embodiment, a mass ratio between the polysaccharides of Aphanothece sacrum and the extract of Gloiopeltis furcata is 1: (1-9).

[0008] According to one embodiment, a weight average molecular mass of Aphanothece sacrum polysaccharides is (1.2-2.0) x 107 g / mol; and / or, a weight average molecular mass of Gloiopeltis furcata extract is (4.5-5.5) x 104 g / mol.

[0009] According to one embodiment, the weight percentage of butylene glycol in the anti-wrinkle composition is less than 77% by weight, based on a weight percentage of the anti-wrinkle composition of 100% by weight.

[0010] According to one embodiment, the total saccharide content of the anti-wrinkle composition is 0.5 to 0.7%.

[0011] According to another aspect, the present disclosure relates to uses of the anti-wrinkle composition in the preparation of a cosmetic product.

[0012] According to another aspect, the present disclosure relates to a cosmetic product containing said anti-wrinkle composition.

[0013] According to one embodiment, the weight percentage of the anti-wrinkle composition in the cosmetic product varies from 0.5 to 10% by weight.

[0014] According to one embodiment, the cosmetic also contains at least one adjuvant acceptable in the field of cosmetics.

[0015] Compared to the prior art, the present disclosure has the following beneficial effects: according to the present disclosure, polysaccharides from Aphanothece sacrum and an extract of Gloiopeltis furcata are used as active ingredients, which interact with each other to produce glycoconjugated structures such as N-acetylgalactosamine (GalNAc) and galactose (a / [3Gal), such glycoconjugated structures produced enhance the effects of the anti-wrinkle composition, such as refreshing, hydrating, preventing damage caused by ultraviolet and anti-wrinkle effects. DESCRIPTION OF THE FIGURES

[0016] [Fig.1] illustrates states of the anti-wrinkle composition of comparative example 2 after being deposited for different durations under different conditions;

[0017] [Fig.2] illustrates the inhibitory effects of the anti-wrinkle compositions of the examples comparatives 3 to 5 on different lectins;

[0018] [Fig.3] illustrates the inhibitory effects of the anti-wrinkle compositions of comparative examples 6 to 8 on the different lectins;

[0019] [Fig.4] illustrates the inhibitory effects of anti-wrinkle compositions in examples of realization 15 to 17 on the different lectins;

[0020] [Fig.5] illustrates the results of immunoblotting the anti-wrinkle composition at different concentrations on HS68 cells exposed to ultraviolet B (UVB) radiation;

[0021] [Fig.6] illustrates the changes observed at the level of wrinkles, including the depth of wrinkles in a volunteer before and after the application of the cream around the eyes in application example 2;

[0022] [Fig.7] illustrates the changes observed at the level of the crow's feet in a volunteer before and after application of the eye contour cream in comparative application example 2;

[0023] [Fig.8] illustrates the changes observed at the level of the crow's feet of a volunteer before and after the application of the face cream in application example 3;

[0024] [Fig.9] illustrates the changes observed in the crow's feet of a volunteer before and after application of face cream in comparative application example 3;

[0025] [Fig. 10] illustrates the changes observed in the wrinkles under the eyes of a volunteer before and after the application of the face cream in application example 3;

[0026] [Fig. 11] illustrates the changes observed in the wrinkles under the eyes of a volunteer before and after the application of the face cream in comparative application example 3. DETAILED DESCRIPTION OF THE INVENTION

[0027] The advantages and features of this disclosure and the methods for realizing said advantages and features will be better understood by referring to the detailed description of the following embodiments. However, this disclosure may be made in any different form and shall not be limited to the embodiments described in the description. By providing the embodiments disclosed herein, the disclosure of this disclosure will be detailed and complete, and the scope of this disclosure will be well communicated to the person skilled in the art.

[0028] The terms used in the description are intended only to describe certain embodiments, rather than to limit this disclosure. Unless otherwise clearly stated, the singular form includes the plural form.

[0029] Unless otherwise indicated, all terms (including technical and scientific terms) used herein have the same meaning as those well known to those skilled in the art. Any term defined in a general dictionary shall be interpreted as having the same meaning in the context of the field concerned and, unless clearly stated otherwise, shall not be interpreted as having an idealistic or excessively formalistic meaning.

[0030] In what follows, the anti-wrinkle composition according to this disclosure and the cosmetics containing the anti-wrinkle composition for hydration, refreshing, anti-wrinkle effect and prevention of damage caused by ultraviolet will be described in detail.

[0031] The term "skin wrinkles" used here refers to fine wrinkles formed on the skin due to skin degradation, which may be related to genetic factors, a decrease in collagen and elastin present in the dermis of the skin, external environmental factors, etc.

[0032] The term "skin anti-wrinkle / anti-wrinkle" used here refers to the prevention or inhibition of the appearance of wrinkles or the improvement of wrinkles already produced.

[0033] The term "ultraviolet damage" used here refers to signs such as sunspots, loss of elasticity, premature aging, sensitivity and the appearance of skin wrinkles which are caused by irritation of the skin by ultraviolet rays, resulting in necrosis of a large number of dermal cells and metabolic disorders and poor metabolism of impurities in the cells.

[0034] The term "prevention of ultraviolet damage" used herein refers to the prevention or inhibition of various skin signs caused by irritation of the skin by ultraviolet rays.

[0035] For example, the term "safe and effective dosage" used herein refers to an amount of a compound or composition sufficient to produce the beneficial effects described herein, but low enough to avoid any serious side effects judged by a person skilled in the art.

[0036] This disclosure provides an anti-wrinkle composition, comprising the following ingredients in parts by weight: 0.1 to 1.5 parts of Aphanothece sacrum polysaccharides, 0.2 to 70 parts of Gloiopeltis furcata extract, 10 to 230 parts of butylene glycol and 50 to 600 parts of water.

[0037] The anti-wrinkle composition according to the present disclosure comprises polysaccharides from Aphanothece sacrum and an extract of Gloiopeltis furcata as active ingredients, which interact with each other to produce glycoconjugated structures such as mannose, glucose, galactose, N-acetylgalactosamine, fucose, rhamnose, and xylitol. According to a first aspect, N-acetylgalactosamine and galactose absorb and retain moisture in the skin to make the skin hydrated and supple and enhance the moisturizing and barrier effects of the anti-wrinkle composition on the skin. In addition, N-acetylgalactosamine and galactose are able to enhance the soothing and anti-inflammatory effects of the anti-wrinkle composition.Secondly, N-acetylgalactosamine promotes the exfoliation of dead skin cells and the removal of keratinized cells, leaving the skin smooth and delicate, and enhancing the anti-wrinkle effect of the anti-wrinkle formula. Thirdly, the anti-wrinkle formula synergistically strengthens the expression of Langerin agglutinin in Langerhans cells, regulates immune function, inhibits the production of reactive oxygen species (ROS) and matrix metalloproteinase (MMPI), improves cell viability and proliferation, promotes the expression of COL1A1 and COL1A2, and promotes the production of hyaluronic acid synthase (HAS1), further enhancing the anti-wrinkle effect of the formula.

[0038] By way of example, the weight parts of the polysaccharides of Aphanothece sacrum may be 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1.0 part, 1.1 part, 1.2 part, 1.3 part, 1.4 part or 1.5 part, but they are not limited to the values ​​indicated, and other values ​​in the context of the description are also applicable.

[0039] By way of example, the weight parts of the extract of Gloiopeltis furcata may be 0.2 parts, 1 part, 5 parts, 10 parts, 13 parts, 17 parts, 20 parts, 22 parts, 25 parts, 28 parts, 30 parts, 33 parts, 35 parts, 37 parts, 40 parts, 42 parts, 45 parts, 47 parts, 50 parts, 53 parts, 55 parts, 58 parts, 60 parts, 62 parts, 65 parts, 67 parts or 70 parts, but they are not limited to the values ​​indicated, and other values ​​in the context of the description are also applicable.

[0040] By way of example, the weight shares of water can be 50 parts, 70 parts, 90 parts, 110 parts, 130 parts, 150 parts, 170 parts, 190 parts, 200 parts, 240 parts, 280 parts, 300 parts, 330 parts, 360 parts, 400 parts, 450 parts, 500 parts, 550 parts or 600 parts, but they are not limited to the values ​​indicated, and other values ​​in the context of the description are also applicable.

[0041] By way of example, the weight parts of butylene glycol may be 10 parts, 20 parts, 30 parts, 40 parts, 50 parts, 60 parts, 70 parts, 80 parts, 90 parts, 100 parts, 110 parts, 120 parts, 130 parts, 140 parts, 150 parts, 160 parts, 170 parts, 180 parts, 190 parts, 200 parts, 210 parts, 220 parts or 230 parts, but they are not limited to the values ​​indicated, and other values ​​in the context of the description are also applicable.

[0042] According to one embodiment, a mass of Aphanothece sacrum polysaccharides is 0.05 to 0.5% of a mass of the anti-wrinkle composition, for example 0.05%, 0.08%, 0.1%, 0.12%, 0.15%, 0.18%, 0.2%, 0.23%, 0.25%, 0.27%, 0.3%, 0.33%, 0.35%, 0.38%, 0.4%, 0.42%, 0.45%, 0.47% or 0.5%, but it is not limited to the values ​​indicated, and other values ​​in the context of the description are also applicable.

[0043] The content of Aphanothece sacrumi polysaccharides in the anti-wrinkle composition affects not only the stability of the anti-wrinkle composition, but also affects the moisturizing and anti-wrinkle effects and the UV damage prevention effect of the composition.If the polysaccharide content of Aphanothece sacrum is too low, the action sites of the Aphanothece sacrum polysaccharides and the Gloiopeltis furcat extract are reduced, thus diminishing the moisturizing and anti-wrinkle effects and the UV damage prevention effect of the anti-wrinkle composition; if the polysaccharide content of Aphanothece sacrum is too high, some insoluble substances will appear in the anti-wrinkle composition, leading to a decrease in the stability and the moisturizing and anti-wrinkle effects and the UV damage prevention effect of the anti-wrinkle composition; when the mass of Aphanothece sacrum polysaccharides is 0.05 to 0.5% of the mass of the anti-wrinkle composition, the stability and the moisturizing and anti-wrinkle effects and the UV damage prevention effect of the anti-wrinkle composition are relatively high.

[0044] According to one embodiment, the mass ratio between the polysaccharides of Aphanothece sacrum and the extract of Gloiopeltis furcata is 1:(1-9), for example 1:1; 1:1.5; 1:2; 1:2.5; 1:3; 1:3.5; 1:4; 1:4.5; 1:5; 1:5.5; 1:6; 1:6.5; 1:7; 1:7.5; 1:8; 1:8.5 or 1:9, but it is not limited to the values ​​indicated, and other values ​​in the context of the description are also applicable.

[0045] The moisturizing and anti-wrinkle effects of the resulting anti-wrinkle composition increased by 5 to 10% when the ratio of the mass of Aphanothece sacrum polysaccharides to the mass of Gloiopeltis furcata extract was in a range of 1:(1-9), compared to a ratio outside the range of 1:(1-9).

[0046] According to one embodiment, the average molecular mass by weight of the polysaccharides of Aphanothece sacrum is (1.2-2.0) x 10⁷ g / mol; for example l,2x 107 g / mol, l,4x 107 g / mol, l,6x 107 g / mol, l,8x 107 g / mol, 2,0x 107 g / mol, but it is not limited to the values ​​indicated, and other values ​​in the context of the description are also applicable.

[0047] According to one embodiment, an average molecular mass by weight of the extract of Gloiopeltis furcata is (4.5-5.5) x 104 g / mol, for example 4.5x 104 g / mol, 4.7x 104 g / mol, 4.9x 104 g / mol, 5.1x 104 g / mol, 5.3x 104 g / mol or 5.5x 104 g / mol, but is not limited to these.

[0048] According to one embodiment, taking into account a mass percentage of the anti-wrinkle composition as 100%, a mass percentage of butylene glycol is less than 77%, preferably less than 65%, preferably even less than 55%, more preferably even less than 25-30%.

[0049] The mass percentage of butylene glycol in the anti-wrinkle composition affects its stability and anti-corrosion effect. The anti-wrinkle composition according to this disclosure does not contain preservatives, and butylene glycol can act as both a preservative and a solvent. If the mass percentage of butylene glycol is too low, the anti-corrosion effect of the anti-wrinkle composition will be degraded, meaning that its shelf life will be significantly shortened. If the mass percentage of butylene glycol is too high, the polysaccharides in the anti-wrinkle composition will precipitate, leading to a degradation of the composition's stability.The inventor has found through studies that when the mass percentage of butylene glycol is within a preferred range, an anti-wrinkle composition with good stability and a good anti-corrosion effect can be obtained.

[0050] According to one embodiment, the total saccharide content in the anti-wrinkle composition is from 0.5 to 0.7%, for example 0.5%, 0.52%, 0.55%, 0.57%, 0.6%, 0.63%, 0.65%, 0.68% or 0.7%, but it is not limited to the values ​​indicated, and other values ​​in the context of the description are also applicable.

[0051] According to one embodiment, an average molar mass of polysaccharides in the anti-wrinkle composition is 7.8 to 8.2 MDa°

[0052] The anti-wrinkle composition of the present disclosure has a high molecular weight; such a high molecular weight anti-wrinkle composition exhibits good moisturizing and anti-wrinkle effects and an effect of preventing damage caused by ultraviolet radiation; and it is known to those skilled in the art that substances of high molecular weight are difficult to dissolve; and the anti-wrinkle composition according to the present disclosure contains a wide variety of glycoconjugated structures, and the heterogeneity of the glycoconjugated structures gives high solubility to the anti-wrinkle composition.

[0053] This disclosure also relates to extraction steps of polysaccharides from Aphanothece sacrum and extract from Gloiopeltis furcat.

[0054] According to one embodiment, first, plant components (plant materials or plant products), such as stems, fragments, leaves, fine powders, dust, and / or coarse grains (shorts), are mixed with a solvent (e.g., water and / or other compounds) at an elevated temperature. For example, several water-miscible solvents (e.g., alcohols, such as ethanol) can be combined with water to form an aqueous solvent. In some cases, the water content of an aqueous solvent can be up to 50% greater by weight than that of the solvent. According to one embodiment, the water content is at least approximately 70%, or at least approximately 80%, or at least approximately 90%, or approximately 100% of the solvent. Demineralized water, distilled water, or tap water can be used.The amount of solvent in the suspension can vary over a wide range, but the amount added is generally about 75% to about 99% by weight of the suspension. However, the amount of solvent can vary depending on the nature of the solvent, the extraction temperature, and the type of plant components.

[0055] Once a solvent / plant component mixture has been formed, some or all of the soluble extract fractions of the component mixture may optionally be separated (e.g., by extraction) from the mixture. If necessary, the aqueous solvent / plant component mixture may be agitated by stirring, vibration, or other mixing means during the extraction process, thereby increasing the extraction rate. Generally, the extraction time is from approximately 0.5 h to approximately 6 h.

[0056] Before the extraction step, an optional grinding or chopping step may be performed to grind the plants or parts of the plants and thus destroy the plant cell walls. Once residual insoluble fractions have been separated from the plant solution, optionally, soluble fractions of the extract may be concentrated using any known type of concentrator (e.g., a vacuum evaporator). In one embodiment, the soluble fractions may be highly concentrated. Furthermore, the concentrated or unconcentrated soluble fractions of the extract may be used in any desired manner.

[0057] According to one embodiment, the extraction can also be carried out by means other than hot water extraction, i.e., by extraction with supercritical gases (e.g., carbon dioxide) or with, for example, ethanol, hexane, acetone, R134a (1,1,1,2-tetrafluoroethane), carbon dioxide, and hydrofluorocarbons. According to one embodiment, the extraction can be carried out with at least one solvent at room temperature and atmospheric pressure. Extraction can also be carried out with mixtures of different solvents. In another embodiment, extraction can be performed with at least one solvent (e.g., R 134a or carbon dioxide) in different states (liquid or gaseous) at different temperatures and pressures. For example, extraction can be carried out with liquid solvents (e.g., volatile or non-volatile solvents at room temperature), subcritical solvents (e.g., water at a temperature above 100 °C and a pressure above 1 bar), or supercritical solvents (e.g., carbon dioxide at a temperature above 31 °C and a pressure above 73 bar).

[0058] For the purposes of this disclosure, extraction may be enhanced through technological aids such as pH adjusters (e.g., NaOH or organic acids), microwaves, pressure, sonication, and enzymes (e.g., proteases, amylases, celluloses, and / or pectinases). In this disclosure, "extraction" means the aforementioned extraction methods provided. The extraction used in this disclosure may be performed continuously or discontinuously.

[0059] According to one embodiment, the extraction and / or pressing can be carried out using at least a portion of fresh, frozen or dried plant material, which is one or more selected from the roots, stems, trunks, main stems, leaves, fruits, flowers, seeds or bark of the plants.

[0060] The soluble fractions (plant extracts) and the insoluble fractions (solid plant particles) can be separated by liquid-solid phase separation, for example by filtration (under or without pressure), centrifugation or other means commonly used in the laboratory and known to technicians.

[0061] A person skilled in the art can use methods well known in the art to homogenize the polysaccharides of Aphanothece sacrum, the extract of Gloiopeltis furcata, butylene glycol, and water to obtain the anti-wrinkle composition, for example, mechanical stirring, homogenization, or ultrasound. A homogeneous and stable anti-wrinkle composition will be obtained after mixing, which allows for thorough mixing of the active ingredients of the anti-wrinkle composition and promotes the complete release of the active ingredients.

[0062] According to one embodiment, a process for preparing Aphanothece sacrum polysaccharides consists of:

[0063] (1) remove water-soluble pigments contained in polysaccharides of Aphanothece sacrum by freeze-thaw, then remove fat-soluble pigments contained in the polysaccharides of Aphanothece sacrum with hypochlorous acid or activated charcoal to obtain a solid, decolorized product;

[0064] (2) dissolve the discolored solid product obtained in step (1) with a solution aqueous sodium hydroxide, then adjust the pH, filter, wash and dry to obtain the polysaccharides of Aphanothece sacrum.

[0065] In particular, the number of freeze-thaw cycles is 2 to 5 times.

[0066] In particular, a mass percentage of sodium hydroxide in the solution aqueous sodium hydroxide is 10 to 18%.

[0067] In particular, the final point of pH adjustment corresponds to pH = 6.0-7.0.

[0068] In particular, the washing solvent is water and isopropanol.

[0069] In particular, the drying should not be limited to a specific method, it may include, for example, air drying, oven drying, freeze-drying, etc.

[0070] According to one embodiment, a process for preparing the extract of Gloiopeltis furcata consists of:

[0071] Grind and degrease Gloiopeltis furcata at room temperature, stir a first product thus obtained in water, then filter, wash and dry to obtain the extract of Gloiopeltis furcata.

[0072] In particular, before grinding and degreasing, Gloiopeltis furcata must be pretreated, including washing and drying. Pretreatment removes impurities from Gloiopeltis furcata, such as sand, dust, and others.

[0073] In particular, the degreasing includes the following steps: refluxing ground Gloiopeltis furcata into powder in ethanol for 2 to 3 hours to remove the fatty fractions of Gloiopeltis furcata; centrifuging degreased Gloiopeltis furcata into powder and drying to constant weight at a temperature of 50 to 65°C.

[0074] More specifically, a ratio of the mass of the first product to the mass of the water is 1:5-20.

[0075] In particular, the washing solvent is water and isopropanol.

[0076] According to a second aspect, the present disclosure provides uses of the anti-wrinkle composition in the preparation of cosmetic products.

[0077] According to a third aspect, the present disclosure provides a cosmetic product containing said anti-wrinkle composition.

[0078] According to one embodiment, a percentage by weight of the anti-wrinkle composition relative to the cosmetic product is from 0.5 to 10%, for example 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5% or 10%, but it is not limited to the values ​​indicated, and other values ​​in the context of the description are also applicable.

[0079] Adding the anti-wrinkle composition in a specific proportion to cosmetic products will provide a good anti-wrinkle effect to the cosmetics. When a cosmetic product according to this application contains less than 0.5% by weight of the anti-wrinkle composition according to the above application, an adequate effect of improving skin elasticity or improving wrinkles or skin hydration cannot be expected, and when it contains more than 10% by weight of the anti-wrinkle composition, adverse reactions such as allergies or skin safety problems may occur.

[0080] According to one embodiment, said cosmetic product may be in emulsion form or in soluble form. For example, this includes lotions such as a softening lotion or a nourishing lotion, milks such as a face milk or a body milk, creams such as a nourishing cream, a moisturizing cream and an eye contour cream, serums, makeup ointments, balms, sprays, gels, masks, sunscreens, primers, foundations such as liquid, solid or spray foundations, powders, makeup removers such as a cleansing cream, a cleansing lotion and a cleansing oil, cleansing products such as a cleansing foam, a soap and a shower gel.

[0081] The cosmetic product also contains at least one adjuvant acceptable in the field of cosmetics; such as fats, wetting agents, nourishing agents, conditioning agents, softeners, thickeners, organic solvents, suspending agents, solubilizers, concentrating agents and gelling agents, antioxidants, stabilizers, foaming agents, perfumes, surfactants, water, ionic or non-ionic emulsifiers, fillers, metal ion blocking and chelating agents, preservatives, vitamins, blocking agents, essential oils, colorants, pigments, hydrophilic or lipophilic active agents, lipid capsules or any other ingredient commonly used in cosmetics.

[0082] The aforementioned components contained in the composition according to this application may each preferably be included in the composition according to this application within a maximum dosage range expressly indicated in the specifications prescribed by the government of each country.

[0083] According to one embodiment, the cosmetic product is an eye contour cream, which comprises the following components in percentage by weight: 0.5-10% anti-wrinkle composition, 0.3-1% p-hydroxyacetophenone, 1-6% butylene glycol, 0.05-0.3% xanthan gum, 0.5-1.5% emulsifier, 0.5-10% polydimethylsiloxane, 0.5-10% caprylic / capric triglyceride, 0.3-1% 1,2-hexanediol and 100% demineralized water; wherein the emulsifier is composed of sodium polyacrylate, ethylhexyl stearate and trideceth-6 in a mass ratio of 62:34:4.

[0084] According to one embodiment, the cosmetic product is a gel, which comprises the following components in percentage by weight: 0.5-10% anti-wrinkle composition, 0.3-1% p-hydroxyacetophenone, 0.5-1.5% emulsifier, 0.3-1.0% 1,2-hexanediol and 100% demineralized water; wherein the emulsifier is composed of sodium polyacrylate, ethylhexyl stearate and trideceth-6 in a mass ratio of 62:34:4.

[0085] According to one embodiment, the cosmetic product is a face cream, which comprises the following components in percentages by weight: 0.5-10% anti-wrinkle composition, 0.5-1% p-hydroxyacetophenone, 0.5-5% butylene glycol, 0.05-0.2% xanthan gum, 0.02-0.5% sodium stearoyl glutamate, 0.3-1.0% ammonium acryloyldimethyltaurate / vinylpyrrolidone (VP) copolymer, 1.0-2.5% a mixture of cetearyl olivate and sorbitan olivate, 0.5-3.0% cetearyl alcohol, 0.5-5.0% caprylic / capric triglyceride, 0.5-5.0% hydrogenated polydecene, 0.5-5.0% polydimethylsiloxane with a kinematic viscosity of 100 cSt, 0.5-5.0% polydimethylsiloxane with a kinematic viscosity of 5 cSt, 0.5-5.0% Limnanthes alba seed oil, 0.5-1.0% 1,2-hexanediol, and 100% demineralized water; wherein, a ratio of the mass of cetearyl olivate to the mass of sorbitan olivate is 5-7:3-5.

[0086] The term "comprises" in this disclosure means that the cosmetic product may include, in addition to the aforementioned raw materials, other raw materials that impart different properties to the cosmetic product. Furthermore, the term "comprises" in this disclosure may also be replaced by the terms "be" or "consist of...".

[0087] It should be noted that, by "100% demineralized water", it is understood that among the raw materials of the eye contour cream according to the present application, with the exception of the anti-wrinkle composition, p-hydroxyacetophenone, butylene glycol, xanthan gum, emulsifier, polydimethylsiloxane, caprylic / capric triglyceride, 1,2-hexanediol and other optional components, the remainder is water; a sum of the weight percentages of the anti-wrinkle composition, p-hydroxyacetophenone, butylene glycol, xanthan gum, emulsifier, polydimethylsiloxane, caprylic / capric triglyceride, 1,2-hexanediol and other components and water is 100% by weight.

[0088] Or, by "100% demineralized water", it is understood that among the raw materials of the gel according to this application, with the exception of the anti-wrinkle composition, p-hydroxyacetophenone, emulsifier, 1,2-hexanediol and other optional components, the remainder is water; a sum of weight percentages of the anti-wrinkle composition, p-hydroxyacetophenone, emulsifier, 1,2-hexanediol and other components and water is 100% by weight.

[0089] Or, by "100% demineralized water", it is understood that among the raw materials of the face cream according to this application, with the exception of the anti-wrinkle composition, p-hydroxyacetophenone, butylene glycol, xanthan gum, sodium stearoyl glutamate, ammonium acryloyldimethyltaurate / VP copolymer, cetearyl olivate and sorbitan olivate mixture, cetearyl alcohol, caprylic / capric triglyceride, hydrogenated polydecene, polydimethylsiloxane with a kinematic viscosity of 100 cSt, polydimethylsiloxane with a kinematic viscosity of 5 cSt, Limnanthes alba seed oil, 1,2-hexanediol, and other optional components, the remainder is water. The above raw materials represent a total percentage by weight of 100% in the face cream.

[0090] According to another aspect, the present disclosure also relates to a process for preparing said gel, which includes the following steps: adding demineralized water, p-hydroxyacetophenone and an emulsifier to a container, heating to 75 to 80 °C and mixing well, homogenizing for 2 to 3 minutes at a speed of 8000 to 100000 rpm, then cooling to 45 °C, successively adding the anti-wrinkle composition and 1,2-hexanediol, and stirring well to obtain.

[0091] According to another aspect, the present disclosure also relates to a process for preparing said eye contour cream, which includes the following steps:

[0092] (1) add demineralized water, p-hydroxyacetophenone, butylene glycol and the xanthan gum in a container, heat to 75-80°C and mix well to obtain phase A, and maintain the temperature for later use;

[0093] (2) add the polydimethylsiloxane and the caprylic / capric triglyceride into a container, heat to 75-80 °C and mix well to obtain phase B, and maintain the temperature for later use;

[0094] (3) add the phase B obtained in step (2) and the emulsifier to the phase A obtained at Step (1), homogenize for 2 to 3 minutes at a speed of 8000 to 100000 rpm, then cool to 45 °C, successively add the anti-wrinkle composition and the 1,2 hexanediol, and shake well to obtain.

[0095] According to another aspect, the present disclosure also relates to a process for preparing said face cream, which includes the following steps:

[0096] (1) add demineralized water, p-hydroxyacetophenone, butylene glycol, the xanthan gum and sodium stearoyl glutamate in a container, heat to 80-85°C and mix well to obtain phase A, and maintain the temperature for later use;

[0097] (2) add a mixture of cetearyl olivate and sorbitan olivate, alcohol cetearyl, caprylic / capric triglyceride, hydrogenated polydecene, polydimethylsiloxane with a kinematic viscosity of 100 cSt, polydimethylsiloxane kinematic viscosity of 5cSt and Limnanthes alba seed oil in a container, heat to 80-85 °C and mix well, add ammonium acryloyldimethyltaurate / VP copolymer and mix well to obtain phase B, and maintain temperature for later use;

[0098] (3) add phase B obtained in step (2) to phase A obtained in step (1), homogenize for 2 to 3 minutes at a speed of 8000 to 100000 rpm, then cool to 45 °C, successively add the anti-wrinkle composition and the 1,2 hexanediol, and shake well to obtain.

[0099] To better understand the present application, the anti-wrinkle composition according to the present application and the preparation process and its effects will be described in more detail below with reference to specific embodiment examples.

[0100] The polysaccharides of Aphanothece sacrum are prepared in our workshop, the preparation process of which consists of:

[0101] (1) remove water-soluble pigments contained in polysaccharides of Aphanothece sacrum by freeze-thaw, then remove fat-soluble pigments contained in the polysaccharides of Aphanothece sacrum with hypochlorous acid to obtain a solid, decolorized product;

[0102] (2) dissolve the discolored solid product obtained in step (1) with a solution aqueous sodium hydroxide having a mass percentage of 10%, a ratio of the mass of the aqueous sodium hydroxide solution to the mass of the decolorized solid product being 20:1, then adjust the pH to pH=6.0-6.5, filter, wash the filter residue obtained 3 times with water and dry to obtain the polysaccharides of Aphanothece sacrum, the average molecular mass by weight of the polysaccharides of Aphanothece sacrum being 1.6x 107 g / mol.

[0103] The extract of Gloiopeltis furcata is prepared in our own facilities, the preparation process of which consists of: washing and drying fresh Gloiopeltis furcata, then grinding and degreasing at room temperature to obtain a first product, thoroughly mixing the first product with water at a mass ratio of 1:10, stirring at room temperature for 24 hours, filtering, washing the filter residue 3 times with water, and drying to obtain the extract of Gloiopeltis furcata, the average molecular mass by weight of the extract of Gloiopeltis furcata being 4.9x 104 g / mol. Examples of implementation and comparative examples

[0104] The components and their weight proportions of the anti-wrinkle compositions in the embodiments and comparative examples are shown in Table 1, and a method for preparing the anti-wrinkle compositions in the embodiments and comparative examples comprises the following steps: under stirring and at a rotational speed of 800 rpm, add the components to a container parts by weight presented in table 1, and shake for 30 minutes to obtain the anti-wrinkle composition.

[0105] [Tables 1] Components (by weight) Water Butanediol Aphanothece sacrum polysaccharides Gloiope extract Itis furcata Example of preparation 1 600 30 0.5 10 Example of preparation 2 220 30 0.5 50 Example of preparation 3 50 10 0.5 70 Example of preparation 4 69 30 0.1 0.1 Example of preparation 5 69 30 0.3 0.5 Example of preparation 6 69 30 0.5 0.5 Example of preparation 7 69 30 1 0.5 Example of preparation 8 69 30 1.5 0.5 Example of preparation 9 69 80 0.5 0.5 Example of preparation 10 69 130 0.5 0.5 Example of implementation 11 69 230 0.5 0.5 Example of implementation 12 69 30 0.2 0.8 Example of implementation 13 69 30 0.1 0.9 Example of implementation 14 69 30 0.6 0.4 Example of implementation 15 69 30 0.24 0.24 Example of implementation 16 69 30 0.12 0.12 Example of implementation 17 69 30 0.06 0.06 Comparative example 1 69 280 0.5 0.5 Comparative example 2 69 30 2.5 0.5 Comparative example 3 69 30 0.24 Comparative example 4 69 30 0.12 Comparative example 5 69 30 0.06 Comparative example 6 69 30 0.24 Comparative example 7 69 30 0.12 Comparative example 8 69 30 0.06

[0106] Example test 1

[0107] In this test, the stability of the anti-wrinkle compositions obtained in the embodiment examples and the comparative examples was tested.

[0108] Test procedure: deposit the anti-wrinkle compositions obtained in the embodiment examples and the comparative examples under the cyclic conditions of -18 °C, 5 °C, room temperature (RT), 40 °C, 50 °C, ultraviolet (UV) radiation and -10 / 45 °C, then remove them at different time points, once returned to room temperature, evaluate the sensory properties and determine the physical-chemical properties according to the following judgment rules: O: normal; +: Degree of discoloration.

[0109] Overall judgment requirements:

[0110] 1. UV radiation requires that DM be stable, and a value less than 14 days was deemed ineligible;

[0111] 2. Temperature stability requires that DiM be stable, and a value less than Dim was deemed ineligible.

[0112] Among them, the results of the color tests of the anti-wrinkle compositions at 50°C and under UV conditions are presented in Table 2.

[0113] [Tables2] Do d7 D14 Dim D2M Dom Sample Run 1 UV OOO + ++ +++ 50°COOOO 0 ++ Sample Run 2 UV OOO + ++ +++ 50°COOOO 0 ++ Run Sample 3 UV + O+OO Ex5 +0 measurement 4 UV OOOO + +++ 50°COOOO + +++ 50°COOOO + +++ 50°COOOO 0 + Sample 6 UV OOO + + +++ 50°COOOO 0 + CO 0 ++ Sample 8 UV OO + ++ +++ +++ 50°COOOO 0 + Sample 9 UV OOO + + +++ 50°COOOO 0 + Sample 10 UV OOO + + +++ Example O1 of 50 UV +COO + +++ 50°COOOO 0 + Reference Sample 12 UV OOOO + +++ 50°COOOO 0 + Reference Sample 13 UV OOOO + +++ 50°COOOO 0 + Reference Sample 14 UV +O+OO +0 Example of réalisation 15 UV OOOO + +++ 50°COOOOO + Example of réalisation 16 UV OOOO + +++ 50°COOOOO + Example of réalisation 17 UV OOOO + +++ 50°COOOOO + Example of comp aratif 1 UV OOOO + +++ 50°COOOOO More comp aratif 6 UV OOOO + +++ 50°COOOOO + Example comp aratif 7 UV OOOO + +++ 50°COOOOO + Example comp aratif 8 UV OOOO + +++ 50°COOOOO +

[0114] It can be observed through testing that the anti-wrinkle compositions of embodiments 1 to 17 and comparative examples 3 to 8 had a transparent and / or translucent liquid appearance, and after being deposited for 3 months under cyclic conditions of -18 °C, 5 °C, RT, 40 °C, 50 °C, UV and -10 / 45 °C, no significant variation in the appearance of the anti-wrinkle compositions of embodiments 1 to 17 and comparative examples 3 to 8 was observed. The anti-wrinkle composition of comparative example 1 had a liquid appearance containing flaky substances, and after being deposited for 3 months under cyclic conditions of -18 °C, 5 °C, RT, 40 °C, 50 °C, UV and -10 / 45 °C, the quantity of flaky substances increased significantly. The anti-wrinkle composition of comparative example 2 had a liquid appearance containing insoluble substances, and after being deposited for 3 months under cyclic conditions of -18 °C, 5 °C, RT, 40 °C, 50 °C, UV and -10 / 45 °C, no significant variation in the appearance of the anti-wrinkle composition of comparative example 2 was observed.

[0115] For the anti-wrinkle compositions of embodiment examples 1 to 17 and comparative examples 1 to 8, after being deposited for 3 months under cyclic conditions of -18 °C, 5 °C, RT, 40 °C, 50 °C, UV and -10 / 45 °C, no significant variation in odor was observed.

[0116] For the anti-wrinkle compositions of embodiments 1 to 17 and comparative examples 1 to 8, after being deposited for 3 months under cyclic conditions of -18 °C, 5 °C, RT, 40 °C and -10 / 45 °C, no significant color variation was observed. When deposited at 50 °C and under UV conditions, the color variations of the anti-wrinkle compositions of embodiments 1 to 17 and comparative examples 1 to 8 at different time points are shown in Table 2.As can be seen in Table 2, the color variations of the anti-wrinkle compositions according to this disclosure meet the stability requirements, while the butylene glycol content of Comparative Example 1 was too high, and the composition began to brown at the end of 2 months of deposition under UV conditions, indicating that the stability of the anti-wrinkle composition of Comparative Example 1 was poor; the Aphanothece sacrum polysaccharide content of Comparative Example 2 was too high and it began to brown at the end of 7 days of deposition under UV conditions, indicating that the stability of the anti-wrinkle composition of Comparative Example 2 was poor.

[0117] Figures 1 and 2 illustrate the states of the anti-wrinkle composition of Comparative Example 2 after being deposited for different durations under different conditions. As can be seen in Figure 1, the anti-wrinkle composition of Comparative Example 2 begins to brown after 7 days of deposition under UV conditions, and the color deepened further with increasing deposition time; after 1 month of deposition at 50°C, the color turned yellow.

[0118] Example test 2

[0119] In this test, the glycoconjugated structures contained in the anti-wrinkle compositions of embodiment examples 15 to 17 and comparative examples 3 to 8 were tested.

[0120] In this test, by determining the interactions between the anti-wrinkle compositions of embodiment examples 15 to 17 and comparative examples 3 to 8 and 25 agglutinins, the glycoconjugated structures contained in the anti-wrinkle compositions could be identified. A sample's ability to be identified by agglutinins may to be evaluated by obtaining glycan profiles of the sample from different agglutinins, as illustrated in Figures 2 to 4 and Table 3.

[0121] Table 3 Inhibition rates of anti-wrinkle compositions in embodiment examples 15 to 17 and comparative examples 3 to 8 on each agglutinin (in %) Agglutinins Example of realization 1 5 Example of realization 1 6 Example of realization 1 7 Comparative example 3 Comparative example 4 Comparative example 5 Comparative example 6 Comparative example 7 Comparative example 8 Intera were ConA 66.6 42.5 42.5 20.73 10.50 2.29 69.7 44.5 16.57 Glc / Ma n PSA 63.5 31.7 22.6 39.40 4.02 2.73 58.2 20.4 8.678 Glc / Ma n FimH 65.9 58.6 28.6 -5.14 -41.87 0.83 62 50 30 Man NPA 77.1 59.7 53.1 25.84 1.24 2.47 88.6 65.9 45.59 Man DC-SIG N 76.1 55.5 19.5 16.71 5.01 -4.15 71.5 27.9 3.68 Man Langer in 84.8 71.9 42.9 62.18 52.11 11.40 47.4 12.3 4.19 Man, F UC Dectinl -6.75 -0.96 -14.5 4.80 1.75 3.06 -867 -617 -583 [3-glu can EPS 24.2 5.93 1.81 -5.33 -1.81 -5.10 26.3 7.69 1.67 Gai NAc DBA 37.6 27.7 19.6 -21.36 -11.74 -3.54 18.7 -1.78 -2.262 Gai NAc MPA -12.1 -28.6 -32.5 -2.76 -0.63 -1.21 29.5 3.53 -1.58 Gay NAc, a / [3 Gay AIA 54.8 37.6 19.9 18.34 0,89 -4,47 32,6 4,88 -8,819 a / [3 Gai GSL- Ib4 -5,56 -15,3 -25 -11,85 -45,99 -20,56 12,8 8,68 5,023 a-Gal PA-IL -2,47 -5,98 -1,6 1,73 -2,34 -4,97 -1,27 -1,23 -6,377 a-Gal PNA 3,45 14,2 17,6 -39,36 -25,30 -14,46 12,9 15,2 9,195 [3-Gal Galect in 1 -4,21 3,65 -3,09 -13,45 -8,92 -4,09 1,97 14,8 23,33 [3-Gal . Galect in 3 80,6 66,8 23,2 53,30 16,04 -5,19 58,3 28,4 19,1 [3-Gal DSA -2,51 -4,36 1,71 -14,74 -3,94 2,06 -4,96 -2,59 0,345 Glc NAc GSL-II -195 -240 -217 342,82 289,89 257,27 -227 -228 -222,3 Glc NAc WGA 75,2 67,4 38,2 -7,81 -4,04 -4,25 72,4 56,4 32,53 Glc NAc Layilin -30,3 -185 -217 111,70 121,97 112,32 -134 -154 -145 GAG CD44 -25,2 -26,7 -5,83 3,99 0,22 -8,65 -15 -15 -9,6 GAG UEA-I 50,8 28,3 15,9 3,67 5,07 9,10 16,7 11,3 3,269 Fuc LTA 81,5 47,1 35 45,02 35,01 30,23 21,7 7,9 9,3 Fuc CorM 63,1 44,7 39,6 -15,89 -0,52 -2,34 65,2 51,7 15,02 Rha RFL 9,34 2,81 -0,14 3,43 1,39 0,88 10,8 5,21 3,18 GalU nlXyl 46,9 39 29 20,86 -21,58 -17,27 48,9 39,3 35,86 Xyl nlGU 17,8 -0,67 8,05 -32,02 -33,77 -10,96 15,8 13 16,88 GlcU

[0122] Note: Fuc: fucose; GLC: glucose; Man: mannose; GalNAc: N-acetylgalactosamine; GlcNAc: N-acetylglucosamine; GlcU: glucuronic acid; Rha: rhamnose; Xyl: xylose; [Sglucan: [3-glucan; GAG: glycosaminoglycan; GalU: galacturonic acid; aGal: α-galactose; [3Gal: [3-galactose;

[0123] ConA: concanavalin A; PSA: pea agglutinin; FimH: Escherichia coli adhesion agglutinin; NPA: daffodil agglutinin; DC-SIGN: dendritic cell-specific intercellular adhesion molecule - non-integrin molecule linked to 3; Langerin: Langerhans cell-specific protein; Dectinl: dendritic cell-associated plant C-type agglutinin 1; BPA: Bauhinia agglutinin; DBA: Dolichos biflorus agglutinin; MPA: Maclura pomifera agglutinin; AIA: Artocarpus-Photinia integrifolia agglutinin; GSL-Ib4: ghriffonia seed agglutinin I isoagglutinin B4; PA-IL: galactose-specific agglutinin from Pseudomonas aeruginosa; PNA: peanut agglutinin; Gaagglutinin 1: gaagglutinin-1; Gaagglutinin 3: gaagglutinin-3; DS A: Datura stramonium agglutinin; GSL-II: Griffonia II seed agglutinin; WGA: wheat germ agglutinin; Layilin: transmembrane glycoprotein receptor;CD44: peanut agglutinin-linked glycoprotein; UEA-I: vitex I agglutinin; LT A: lotus agglutinin; CorM: whitefish agglutinin; RFL: identifying agglutinin; glucose-1-phosphouridyltransferase (GalU); nlXyl: specific identification of xylose; nlGU: specific identification of N-acetylglucosamine.

[0124] [Fig.2] is a view illustrating the inhibition of the anti-wrinkle compositions of comparative examples 3 to 5 on different agglutinins, [Fig.3] is a view illustrating the inhibition of the anti-wrinkle compositions of comparative examples 6 to 8 on different agglutinins, and [Fig.4] is a view illustrating the inhibition of the anti-wrinkle compositions of embodiment examples 15 to 17 on different agglutinins.As can be seen from the test data presented in Figures 2 to 4 and Table 3, the anti-wrinkle composition containing only Aphanothece sacrum polysaccharides or Gloiopeltis furcata extract had little or no inhibitory effect on DBA (Dolichos biflorus agglutinin) and AIA (Artocarpus-Photinia integrifolia agglutinin) at low concentrations, whereas the anti-wrinkle composition containing both Aphanothece sacrum polysaccharides and Gloiopeltis furcatax extract could synergistically enhance the effect of the anti-wrinkle composition on agglutinins such as DBA, AIA, Langerin (a specific protein of Langerhans cells) and Gal3 (gaagglutinin-3); This demonstrates that the polysaccharides of Aphanothece sacrum and the extract of Gloiopeltis furcatax in the anti-wrinkle composition according to this application have a synergistic effect.

[0125] Example test 3

[0126] In this test, the UV damage prevention effect of the anti-wrinkle composition of embodiment example 16 was tested.

[0127] 1. Materials

[0128] Human dermal fibroblast HS68 (CRL-1635), stored at the USA Culture Collection Center (ATCC); DMEM (Dulbecco's Modified Eagle Medium), penicillin, streptomycin, cinnamyl alcohol, 4-(2-hydroxyethyl)-l-piperazinethanesulfonic acid (HEPES), a cocktail of phosphatase inhibitors and Triton X-100, purchased from Nacalai Tesque (Kyoto, Japan); ethylenediamine tetraacetic acid (EDTA), skimmed milk powder, Tween 20 and dithiothreitol (DTT), purchased from Wako Pure Chemical (Osaka, Japan); insulin-like growth factor 1 (IGF-1), purchased from Abcam (Tokyo, Japan); the nitrocellulose membrane (Hybond-ECL membrane), purchased from GE Healthcare UK, Ltd (Buckinghamshire, UK), a cocktail of protease inhibitors, purchased from Roche Applied Science (Mannheim, Germany);fetal bovine serum (FBS), purchased from Invitrogen (Carlsbad, CA, USA); an EZ-ECL chemiluminescence detection kit, purchased from the Israeli Bioindustry Company (Kibbutz Beit Haemek); and the anti-wrinkle composition from example realization 16.

[0129] 2. Cell culture

[0130] Human dermal fibroblast HS68 (CRL-1635) was incubated on DMEM medium containing 10% (V / V) FBS, penicillin at 100 U / mL and streptomycin at 100 pg / mL under 5% CO2 and at 37°C.

[0131] 3. Test methods

[0132] 3.1 Effects of the anti-wrinkle composition on HS68 cell toxicity

[0133] Deposit a normal control group and an irradiated group composed of anti-wrinkle compositions of different doses (the irradiated group was divided into irradiated groups of anti-wrinkle composition of 0.01, 0.1, 1, 5 and 10 pg / mL, respectively) on a 96-well plate, collect HS68 cells in logarithmic growth phase and deposit on the 96-well plate at a density of lxl04 / well, with 6 test wells per group;Fill the wells to the edges with sterile phosphate buffer (PBS) and incubate under 5% CO2 at 37 °C for 24 h, until the cells are completely adhered to the wall, add the anti-wrinkle compositions of the above concentrations to the irradiated group on the 96-well plate at a rate of 50 pL / well, continue incubating for 24 h, aspirate and discard the medium, then add the same amount of DMEM medium and 20 pL of thiazole blue (MTT) solution (5 mg / mL) to each well and incubate for 4 h, aspirate and discard the medium containing MTT, add 200 pL of dimethyl sulfoxide (DMSO) to each well to resolve a crystallization product and determine an absorbance value at 570 nm using a microplate reader. Cell survival rate (%) = absorbance value of the irradiated group / absorbance value of the control group x 100%.

[0134] 3.2 Effects of the anti-wrinkle composition on UVB-induced HS68 cells

[0135] Deposit a negative control group (not treated with the anti-wrinkle composition and UVB) and an irradiated group composed of the anti-wrinkle compositions of different doses (the irradiated group was divided into irradiated groups with anti-wrinkle compositions of 0, 0.01, 0.1, 1, 5 and 10 pg / mL, respectively) on a 96-well plate, collect HS68 cells in logarithmic growth phase and deposit on the 96-well plate at a density of lxl04 / well, with 6 test wells per group;Fill the wells to the edges with sterile phosphate buffer and incubate under 5% CO2, at 37°C for 24 h, until the cells are completely adhered to the wall. Add the anti-wrinkle compositions of the above concentrations to the irradiated group on the 96-well plate at a rate of 50 pL / well. Continue incubating for 24 h. Aspirate and discard the medium. Wash with PBS. Treat the cells with UVB using a UVB crosslinker (Analytik Jena US, Upland, California (CA), USA) at a dose of 30 mJ / cm2. After treatment, the MTT test was performed, and the specific test procedure was the same as "3.1".

[0136] 3.3 Determination by DCF (2',7'-dichlorofluorescein) fluorescence of the levels of ROS in HS68 cells

[0137] Inoculate and treat HS68 cells using the "3.2" method, then stain the cells with 1OpM of 2',7'-dichlorodihydrofluorescein (DCFH-DA) and analyze using an Axiovert 200M fluorescence spectrophotometer (Zeiss Company, Oberkochen, Germany). The level of intercellular reactive oxygen species (ROS) was displayed by DCFH-DA fluorescence and measured using a microplate reader (Infinity M200 Pro, Tecan, Switzerland) at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

[0138] 3.4 SDS-PAGE and Western blot analysis

[0139] Inoculate and treat HS68 cells by the "3.2" method, take a cell suspension from each group, perform centrifugation to remove the supernatant, then add 100 pL of cell lysate (protease inhibitor: Ix radioimmunoprecipitation test buffer (RIPA) (10 mM tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% polyethylene glycol octylphenyl ether (Triton X-100), 0.1% sodium dodecyl sulfate (SDS) and 1 mM ethylenediamine tetraacetic acid (EDTA))) to lyse the cells, then treat under ultrasound for 10 seconds. Determine the protein concentration of each lysate using a BCA (Bicinchoninic Acid) protein concentration determination kit.

[0140] Reduce with 50 mM dithiothreitol (DTT), inject the proteins onto an 8% SDS polyacrylamide gel, transfer to a nitrocellulose membrane, incubate with 1x TBST (Tris Buffered Saline with Tween-20) buffer containing 5% skimmed milk for 1 h at room temperature, and wash 3 times in 1x TBST buffer for 10 min. Add the nitrocellulose membrane containing the protein of interest to a corresponding primary antibody solution and incubate overnight in an incubator at 4°C. After overnight incubation, shake three times with 1x TBST in an incubator at room temperature for 20 to 30 minutes each time. Add the corresponding secondary antibody solution, incubate in the shaker at room temperature, protected from light, for 2 hours, then shake three times with 1x TBST at room temperature for 30 minutes each time. Incubate with the horseradish peroxidase (HRP) conjugated secondary antibody for 1 hour at room temperature.

[0141] Antibodies against matrix metalloproteinase 1 (MMPI), hyaluronic acid synthase 1 (HAS1), type I collagen alpha 1 chain (COL1A1), type I collagen alpha 2 chain (COL1A2), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from Cell Signaling Technologies (Danver, USA). The levels of MMP-1, HAS1, C0L1A1 and COL1A2 were determined by scanning the nitrocellulose membrane containing the target protein using a chemiluminescence imaging system (Bio-Rad).

[0142] 3.5 Real-time fluorescent quantification polymerase chain reaction (qPCR)

[0143] Place a negative control group (not treated with the anti-wrinkle composition and UVB) and an irradiated group composed of anti-wrinkle compositions at different doses (in addition, the irradiated group was treated with anti-wrinkle compositions of 0, 0.01, 0.1, 1 and 5 qg / mL, respectively) on a 6-well plate, harvest HS68 cells in logarithmic growth phase, incubate under 5% CO2, at 37 °C for 24 h, until the cells are completely adherent to the wall, add the anti-wrinkle compositions of the above concentrations to the irradiated group on the 6-well plate at a rate of 50 qL / well, continue incubating for 24 h, aspirate and discard the medium, wash with PBS, and treat the cells with UVB using a UVB crosslinker (Analytik Jena Company, US, Upland, California (CA), USA), at a dose of 30mJ / cm2. After treatment, collect total RNA using an RNeasy Mini RNA isolation kit (Qiagen Company, Valencia, CA, USA).Elute the RNA in RNase-free water, quantify using UV absorbance, and store at -80°C until use. Perform reverse transcription (RT)-PCR on an Applied Biosystems 7500 Real-Time PCR system under the following amplification conditions: Pre-incubate at 95°C for 10 min, run 40 cycles at 95°C with each cycle lasting 10 seconds, anneal at 60°C for 15 seconds, and extend at 72°C for 15 seconds. Normalize gene expression levels according to GAPDH standards and calculate using the comparative AACT method.

[0144] 3.6 Statistical Methods

[0145] Repeat all trials in parallel three times, and express the results as mean ± standard deviation (SD). Perform a statistical analysis using SPSS (Statistical Product and Service Solutions) software (SPSS, Inc., Tokyo, Japan). Depending on the nature and distribution of the data, perform a Student's t-test, ANOVA, and the appropriate HSD (Tukey's Honestly Significant Difference Test). P < 0.05 was statistically significant. The results are presented in Tables 4 to 7 and [Fig. 5].

[0146] 4. Results and analyses

[0147] 4.1 Effects of the anti-wrinkle composition on HS68 cell toxicity

[0148] As can be seen in Table 4, the anti-wrinkle compositions at different concentrations did not exhibit any significant toxic effect on the cells after 24 h of intervention. Compared to the normal control group, with increasing concentration of the anti-wrinkle composition, no significant variation in cell survival rate was observed, and the difference was not statistically significant. significant. (P>0.05). Therefore, pretreatment with the anti-wrinkle composition at different concentrations had no significant cytotoxic effect on the survival rate of HS68 cells and had little effect on the survival rate of HS68 cells.

[0149] Table 4 Effects of anti-wrinkle compositions of different concentrations on HS68 cell toxicity Concentration Control Group Normal 0.01 qg / mL 0.1 qg / mL 1 qg / mL 5 qg / mL 10 qg / mL Survival Rate of United States in % 100 100.64 ± 6.58 118.52 ± 14.45 115.65 ± 15.75 113.12 ± 13.14 114.45 ± 6.36

[0150] 4.2 Effects of the anti-wrinkle composition on HS68 cell survival induced by UVB

[0151] As can be seen in Table 5, compared to the normal control group, the survival rate of HS68 cells after UVB irradiation was 73.43%, and the protective effect on HS68 cells was dose-dependent when the concentration of the anti-wrinkle composition was in the range of 0.01 to 0.1 qg / mL. When the concentration of the anti-wrinkle composition was 0.1–5 qg / mL, it had a good proliferation effect on HS68 cells, which was significantly different from that of the group not treated with the anti-wrinkle composition (P<0.01).

[0152] Table 5 Effects of anti-wrinkle compositions of different concentrations on UVB-induced HS68 cell survival Concentration Control Group n negative 0 qg / m L 0.01 qg / m L 0.1 qg / mL 1 qg / m L 5 qg / m L 10 qg / mL Cell Survival Rate in % 100 73.43± 9.8 82.4±4.74 100.98 ±7.74 101.8± 8.8 104.06 ±14.72 102.54 ±6.57

[0153] 4.3 Effects of the anti-wrinkle composition on ROS levels in HS68B cells induced by UVB

[0154] As can be seen in Table 6, the ROS content in HS68B cells increased to 175.9% by UVB irradiation. The scavenging effect of the anti-wrinkle composition on ROS caused by UVB damage increased progressively with increasing anti-wrinkle composition concentrations, which was dose-dependent. Among them, when the anti-wrinkle composition at 0.01–5 qg / mL acted on the cells In HS68 irradiated by UVB, the level of ROS in the cells decreased significantly compared to the group not treated with the anti-wrinkle composition, and decreased further with increasing dose (P < 0.01).

[0155] Table 6 Effects of anti-wrinkle compositions of different concentrations on the level of ROS in UVB-induced HS68B cells Concentration n Control group negative 0 qg / mL 0.01 qg / mL 0.1 qg / mL 1 qg / mL 5 qg / mL Variations in ROS content in % 100 175.9+5.3 5 131.2+4.2 2 126.13+4.87 113.4+4.0 8 111.4+4.5 9

[0156] 4.4 Effects of the anti-wrinkle composition on the expression of proteins associated with UVB-induced HS68 cells

[0157] (1) The anti-wrinkle composition inhibits the production of matrix metalloproteinase 1 (MMPI) induced by UVB in HS68 cells

[0158] The test results are presented in Table 7. UVB irradiation promotes DNA damage in skin cells by producing oxidative stress and ROS, leading to further structural and functional damage. Increased MMPI expression due to UVB irradiation is one of the key factors leading to protein degradation in the extracellular matrix (ECM). An anti-wrinkle composition at 0.01 to 5 qg / mL could reduce MMPI expression, which was dose-dependent. Compared to the irradiated group not treated with the anti-wrinkle composition, the reduction in MMPI production was statistically significant (P < 0.01) even when HS68 cells were treated with an anti-wrinkle composition at 0.01 qg / mL.

[0159] Table 7 Effects of anti-wrinkle compositions of different concentrations on UVB-induced HS68 cell-associated protein expression Concentration Variation in MMPI content (%) Variation in MMPI mRNA expression level (%) Variation in HAS1 content (%) Variation in HAS1 mRNA expression level (%) Variation in COL1A1 mRNA expression level (%) Variation in COL1A2 mRNA expression level (%) Negative control group 100 1 100 1 100 100 0 qg / mL 977.33 ±33.98 1.6219 ±0.05 56.67 ±3.5 6 0.533 ±0.058 62.603 5 ±1.09 60.325 2 ±2.13 0.01 qg / mL 846.67 ±11.78 1.0356 ±0.03 91.33±2.8 6 0.9209±0.017 88.6212±1.6 84.709 2±1.12 0.1 qg / mL 843.33 ±13.59 0.9696 ±0.002 98±1.41 0.9981±0.043 89.954 5±l.70 84.924 3±1.36 1 qg / mL 713 ±41.68 0.9159 ±0.02 97.33±0.8 2 l.0969±0.099 98.450 5±0.43 94.256 4±1.43 5 qg / mL 704.67 ±19.75 0.9090 ±0.01 101.67±l, 78 l,1085±0.027 101.05 7±1.14 97.499 9±3.51

[0160] (2) The anti-wrinkle composition promotes the production of acid synthase UVB-induced hyaluronic acid 1 (HAS1) in HS68 cells

[0161] Hyaluronic acid synthase 1 is an enzyme that plays a major role in the production of hyaluronic acid in the skin. The test results are presented in Table 7. After UVB irradiation, HAS1 in HS68 cells was significantly reduced, meaning that the anti-wrinkle composition could increase UVB-induced HAS1 production in HS68 cells. Compared to the irradiated group not treated with the anti-wrinkle composition, HAS1 production was statistically significant (P < 0.01) when HS68 cells were treated with an anti-wrinkle composition at 0.01 to 5 qg / mL.

[0162] (3) The anti-wrinkle composition promotes the production of the alpha 1 chain of collagen type I (COL1A1) and UVB-induced alpha 2 chain of type I collagen (COL1A2) in HS68 cells

[0163] Collagen is an important ECM protein, and type I collagen represents approximately 80% of dermal collagen. Type I collagen consists of two chains, the α1(I) chain and the α2(I) chain, which are encoded respectively by Two genes, C0L1A1 and C0L1A2, were identified. Protein expression levels of C0L1A1 and C0L1A2 were assessed by Western blot and qPCR, and the test results are presented in Figure 5 and Table 7. UVB irradiation reduces the production and expression of type 1 collagen subunits, and this reduction was effectively inhibited by pretreatment with the anti-wrinkle composition at all tested concentrations. Compared to the irradiated group not treated with the anti-wrinkle composition, the production of C0L1A1 and C0L1A2 was statistically significant (P < 0.01) when HS68 cells were treated with an anti-wrinkle composition at concentrations of 0.01 to 5 µg / mL.

[0164] Of all the above, the anti-wrinkle composition according to the present disclosure could effectively prevent damage caused by ultraviolet radiation.

[0165] Application Example 1

[0166] The present application example provides a gel, which comprises the following components in percentage by weight: 1% of the anti-wrinkle composition of the embodiment example 6, 0.5% of p-hydroxyacetophenone, 0.8% emulsifier, 0.5% of 1,2-hexanediol and 100% demineralized water; wherein the emulsifier is composed of sodium polyacrylate, ethylhexyl stearate and trideceth-6 in a mass ratio of 62:34:4.

[0167] This application example also provides a method for repairing said gel, comprising the following steps:

[0168] Add demineralized water, p-hydroxyacetophenone and emulsifier to a container, heat to 78 °C and mix well, homogenize for 3 minutes at a speed of 9000 rpm, then cool to 45 °C, successively add the anti-wrinkle composition of embodiment example 6 and 1,2 hexanediol, and shake well to obtain.

[0169] Application Example 2

[0170] The present application example provides an eye contour cream, which comprises the following components in percentage by weight: 5% of the anti-wrinkle composition of embodiment example 6, 0.5% p-hydroxyacetophenone, 3% butylene glycol, 0.2% xanthan gum, 1% emulsifier, 5% polydimethylsiloxane, 3% caprylic / capric triglyceride, 0.5% 1,2-hexanediol and 100% demineralized water; wherein the emulsifier is composed of sodium polyacrylate, ethylhexyl stearate and trideceth-6 in a mass ratio of 62:34:4.

[0171] This application example also provides a method for repairing said eye contour cream, comprising the following steps:

[0172] (1) add demineralized water, p-hydroxyacetophenone, butylene glycol and xanthan gum in a container, heat to 78°C and mix well to obtain phase A, and maintain the temperature for later use;

[0173] (2) add polydimethylsiloxane and caprylic / capric triglyceride into in a container, heat to 78°C and mix well to obtain phase B, and maintain the temperature for later use;

[0174] (3) add the phase B obtained in step (2) and the emulsifier to the phase A obtained In step (1), homogenize for 3 minutes at a speed of 9000 rpm, then cool to 45 °C, successively add the anti-wrinkle composition from example embodiment 6 and the 1,2 hexanediol, and shake well to obtain.

[0175] Application Example 3

[0176] The present application example provides a face cream, which comprises the following components in percentages by weight: 1% anti-wrinkle composition, 0.5% p-hydroxyacetophenone, 3% butylene glycol, 0.12% xanthan gum, 0.05% sodium stearoyl glutamate, 0.6% ammonium acryloyldimethyltaurate / vinylpyrrolidone (VP) copolymer, 1.8% a mixture of cetearyl olivate and sorbitan olivate, 2% cetearyl alcohol, 4% caprylic / capric triglyceride, 2% hydrogenated polydecene, 2% polydimethylsiloxane with a kinematic viscosity of 100 cSt, 2% polydimethylsiloxane with a kinematic viscosity of 5 cSt, 2% seed oil of Limnanthes alba and 1% of 1,2-hexanediol; in which, a ratio of the mass of cetearyl olivate to the mass of sorbitan olivate is 6:4.

[0177] This application example also provides a method for repairing said face cream, comprising the following steps:

[0178] (1) add demineralized water, p-hydroxyacetophenone, butylene glycol, the xanthan gum and sodium stearoyl glutamate in a container, heat to 82°C and mix well to obtain phase A, and maintain the temperature for later use;

[0179] (2) add a mixture of cetearyl olivate and sorbitan olivate, alcohol cetearyl, caprylic / capric triglyceride, hydrogenated polydecene, kinematic viscosity polydimethylsiloxane of 100 cSt, kinematic viscosity polydimethylsiloxane of 5 cSt and Limnanthes alba seed oil in a container, heat to 80 °C and mix well, add ammonium acryloyldimethyltaurate / vinylpyrrolidone (VP) copolymer and mix well to obtain phase B, and maintain the temperature for later use;

[0180] (3) add the phase B obtained in step (2) and the emulsifier to the phase A obtained In step (1), homogenize for 3 minutes at a speed of 9000 rpm, then cool to 45 °C, successively add the anti-wrinkle composition from example embodiment 6 and the 1,2 hexanediol, and shake well to obtain.

[0181] Comparative application example 1

[0182] The present comparative application example provides a gel; the difference between this comparative application example and application example 1 is that that: demineralized water had replaced the anti-wrinkle composition of example embodiment 6, that is to say that the present comparative application example does not contain the anti-wrinkle composition of example embodiment 6.

[0183] The gel preparation process in this comparative application example is the same as that in application example 1.

[0184] Comparative application example 2

[0185] The present comparative application example provides an eye contour cream; the difference between the present comparative application example and application example 2 is that: demineralized water has replaced the anti-wrinkle composition of embodiment example 6, i.e., the present comparative application example does not contain the anti-wrinkle composition of embodiment example 6.

[0186] The process for preparing the eye contour cream in this comparative application example is the same as that in application example 2.

[0187] Comparative application example 3

[0188] The present comparative application example provides a face cream; the difference between the present comparative application example and application example 3 is that: demineralized water has replaced the anti-wrinkle composition of embodiment example 6, i.e., the present comparative application example does not contain the anti-wrinkle composition of embodiment example 6.

[0189] The process for preparing the face cream in this comparative application example is the same as that in application example 3.

[0190] Example test 4

[0191] In this test, the moisturizing effect of the gels obtained in application example 1 and in comparative application example 1 was tested.

[0192] Test procedure: According to the QB / T 4256-2011 standard "Guide to the Evaluation of the Moisturizing Effect of Cosmetics" recommended for the Chinese light industry, 5 volunteers aged 18 to 65 years were included in the test, and all volunteers signed their consent forms. An application area and a white control area (size: 3 cm x 3 cm) were marked on the inside of the subjects' forearms; no substance was applied to the white control area; samples to be tested were applied in a single dose of (2.0 + 0.1) mg / cm² to the application area respectively; amounts of transdermal water loss of the samples before and after use were measured using a VapoMeter transdermal water loss meter; rate of change of transepidermal water loss (%) = (data after use - data before use) / data before use 100%; The test results are presented in Table 8.As can be seen from the test data in Table 8, the anti-wrinkle composition of this disclosure has a moisturizing effect.

[0193] Table 8 Rate of change in transepidermal water loss Time Control group b lanc Application example comparat if 1 Application example 1 Ih -12.50% -16.02% -6.09%

[0194] Example test 5

[0195] In this test, the anti-wrinkle effect of the eye contour creams obtained in application example 2 and in comparative application example 2 was tested.

[0196] Test procedure: 9 volunteers aged 35 to 45 years were included in the test, and all volunteers signed their consent forms. The volunteers were asked to apply the eye contour creams obtained in application example 2 and in comparative application example 2, once a day for 14 days, with visits on day 0 (baseline value), day 7 and day 14, and a proportion of the area of ​​wrinkles representing in the selected area was measured using a CANFIELD VISIA 7 dermal analysis system, and a maximum depth of wrinkles in the selected area (maximum depression depth), a volume of an area where wrinkles form depressions in the selected area (depression volume) and an overall assessment of a degree of depression of wrinkles in the selected area (depression index / depression score) were determined using a Miravex ANTERA 3D dermal analyzer.All tests were performed after the subjects' faces had been cleaned with the same cleansing product and the subjects had sat quietly in a test environment (temperature of 20±1°C, humidity of 50+10%) for 30 minutes, and the test data were analyzed using IPP and ANTERA CS software, and the test results are presented in Table 9 and Figures 6 and 7.

[0197] [Tables9] Depression Depth (ANTERA3D) Depression Index (ANTERA3D) Depression Volume (ANTERA3D) Air Proportion (VISIA) Application Example 2 D0 100% 100% 100% 12.92% D7 99.1% 97.4% 97.7% / D14 94.3% 92.9% 79.7% 11.01% Comparative Application Example 2 D0 100% 100% 100% 9.11% D7 99.6% 98.1% 97.4% / D14 96.8% 95.2% 88.4% 7.46%

[0198] As can be seen from Table 9 and Figures 6 and 7, the anti-wrinkle composition can effectively improve the depth of wrinkle depression, the depression index and the depression volume of the eye skin, and slightly improve the eye skin area.

[0199] Example test 6

[0200] In the present example of effect, the moisturizing and anti-wrinkle effects of the face creams obtained in application example 3 and in comparative application example 3 were tested.

[0201] Test procedure: 32 volunteers aged 35 to 55 years were included in the test, and all volunteers signed their consents. Volunteers were asked to apply the face creams obtained in application example 3 and in comparative application example 3 to half of the face morning and evening for 28 days, with visits on day 0 (baseline), day 14 and day 28, skin water content was determined using a Comeometer@CM 825 skin moisture measurement probe (Courage&Khazaka, Germany), a transepidermal water loss (TEWL) value of the skin was determined using a Vapometer transepidermal water loss probe (Delfin, Finland), skin elasticity was determined using a Cutometer® Dual MPA 580 skin elasticity probe (Courage Khazaka).Skin color was determined using a Colorimeter CL400 skin color probe, improvements in under-eye wrinkles and crow's feet were determined using VISIA-CR® (Canfield) and PRIMOS, and the degree of crow's feet and the degree of under-eye wrinkles were assessed by the clinical evaluation "Atlas of Skin Aging, Volume 2, Asian Edition".All tests were performed after the subjects' faces had been cleansed with the same cleansing product and the subjects had sat quietly in a test environment (temperature of 20±1°C, humidity of 50+10%) for 30 minutes. The effectiveness of the face cream was expressed as a rate of improvement, rate of change (%) = (data after use - data before use) / data before use x00%. In this example of effect, the data were processed and graphically represented using Office-EXCEL software, and a one-way ANOVA (P<0.005) was performed using SPSS 25.0 software, and all tests were repeated 3 times.The test results are presented in Table 10 and Figures 8 to 11. The skin elasticity measurement value (R2 value) refers to the ratio of the amount of skin recovery without negative pressure to the amount of maximum extension under negative pressure, and the skin elasticity measurement value (R5 value) refers to the ratio of the elastic part in a skin recovery process to the elastic part in a negative pressure process in the first cycle of the skin test.

[0202] [TableauxlO] Indices Groups Initial value 14 days after use 28 days after use Average values ​​Rate of change Average values ​​Rate of change Skin water content Application example 3 33.60 45.82 36.35% 55.73 65.85% Comparative application example 3 33.61 41.50 23.49% 52.99 57.68% Skin TE WL value Application example 3 17.22 16.32 -5.21% 15.07 -12.45% Comparative application example 3 16.79 16.87 0.47% 16.05 -4.45% Measurement value of skin elasticity Skin R2 Application Example 3 0.56 0.60 7.14% 0.67 20.29% Comparative Application Example 3 0.55 0.56 0.27% 0.63 13.12% Measured value of skin elasticity R5 Application Example 3 0.59 0.62 3.51% 0.71 20.12% Comparative Application Example 3 0.60 0.57 -5.34% 0.65 8.36% Crow's feet area Application Example 3 22.53 21.29 -5.53% 20.51 -8.98% Comparative Application Example 3 22.57 22.75 0.80% 22.16 -1,82% Area of ​​wrinkles under the eyes Example of application 3 36.81 32.97 -10.44% 30.13 -18.16% Example of comparative application 3 35.07 36.44 3.89% 33.56 -4.32% , Degree of crow's feet Application example 3 3.84 3.60 -6.19% 3.34 -13.03% Comparative application example 3 3.83 3.61 -5.87% 3.34 -12.89% Degree of wrinkles under the eyes Application example 3 3.74 3.42 -8.53% 3.10 -17.06% Comparative application example 3 3.57 3.34 -6.48% 3.11 -12.78%

[0203] Figures 8 and 9 are views illustrating variations in crow's feet of a volunteer before and after application of the face creams of application example 3 and comparative application example 3, respectively; Figures 10 and 11 are views illustrating variations in under-eye wrinkles of a volunteer before and after application of the face creams from application example 3 and comparative application example 3. As can be seen in Table 10 and Figures 8 to 11, the use of the face cream containing the anti-wrinkle composition according to this disclosure increases / improves skin water content, skin TEWL value and skin elasticity, and simultaneously reduces crow's feet and under-eye wrinkles, indicating that the anti-wrinkle composition according to this disclosure has excellent hydrating, refreshing, skin elasticity-enhancing and anti-wrinkle effects.

[0204] Finally, it should be noted that the above implementation examples are only illustrative to describe the technical solution of this disclosure, rather than to limit the scope of protection of this disclosure. Although this disclosure is described in detail with reference to the implementation examples, those skilled in the art will understand that any equivalent modifications and substitutions to the technical solution of this disclosure without departing from the spirit and scope of this disclosure are possible.

Claims

Demands

1. Anti-wrinkle composition, characterized in that it comprises the following ingredients in the following parts by weight: 0.1 to 1.5 parts of Aphanothece sacrum polysaccharides, 0.1 to 70 parts of Gloiopeltis furcata extract, 10 to 230 parts of butylene glycol and 50 to 600 parts of water.

2. Anti-wrinkle composition according to claim 1, characterized in that the percentage by weight of Aphanothece sacrum polysaccharides in the anti-wrinkle composition varies from 0.05 to 0.5% by mass.

3. Anti-wrinkle composition according to claim 1, characterized in that the mass ratio of Aphanothece sacrum polysaccharides to Gloiopeltis furcata extract is 1: (1-9).

4. Anti-wrinkle composition according to claim 1, characterized in that the average molecular mass by weight of the polysaccharides of Aphanothece sacrum is (1.2-2.0) x 107 g / mol; and / or, the average molecular mass by weight of the extract of Gloiopeltis furcata is (4.5-5.5) x 104 g / mol.

5. Anti-wrinkle composition according to claim 1, characterized in that the percentage by weight of butylene glycol in the anti-wrinkle composition is less than 77% by weight, based on a percentage by weight of the anti-wrinkle composition being 100% by weight.

6. Anti-wrinkle composition according to claim 1, characterized in that a total saccharide content in the anti-wrinkle composition is 0.5 to 0.7%.

7. Use of the anti-wrinkle composition according to any one of claims 1 to 6 in the preparation of a cosmetic product.

8. Cosmetic product, characterized in that it comprises the anti-wrinkle composition according to any one of claims 1 to 6.

9. Cosmetic product according to claim 8, characterized in that the percentage by weight of the anti-wrinkle composition in the cosmetic product varies from 0.5 to 10%.

10. Cosmetic product according to claim 8, characterized in that the cosmetic product further contains at least one adjuvant acceptable in the field of cosmetics.

Images